-
Founded in:
1997-10-17 -
Country:
China -
Address:
No. 219, Qing'an Road, Xinzheng City -
Tax NO.:
91410100712635557P -
Registered Funds:
111.68 million yuan -
Website:
-
Email:
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| ColloidalBismuthPectin |
After oral administration, it can form a protective film on the gastric mucosa and stimulate the gastric mucosal epithelial cells to secrete mucus, increasing the protective effect on the mucosa. In addition, it can kill Helicobacter pylori and promote the healing of gastritis.
More
After oral administration, it can form a protective film on the gastric mucosa and stimulate the gastric mucosal epithelial cells to secrete mucus, increasing the protective effect on the mucosa. In addition, it can kill Helicobacter pylori and promote the healing of gastritis. |
2034-00-2 | 14 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Fluconazole |
This product belongs to the azole antifungal drug with a wide antifungal spectrum. Its mechanism of action is mainly to highly selectively interfere with the activity of fungal cytochrome P-450, thereby inhibiting the biosynthesis of ergosterol on the fungal cell membrane. It is effective against fungal infections in humans and various animals, such as Candida infection, Cryptococcus neoformans infection, Malassezia furfur, Microsporum, Trichophyton, Epidermophyton, etc.
More
This product belongs to the azole antifungal drug with a wide antifungal spectrum. Its mechanism of action is mainly to highly selectively interfere with the activity of fungal cytochrome P-450, thereby inhibiting the biosynthesis of ergosterol on the fungal cell membrane. It is effective against fungal infections in humans and various animals, such as Candida infection, Cryptococcus neoformans infection, Malassezia furfur, Microsporum, Trichophyton, Epidermophyton, etc. |
86386-73-4 | 69 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Fluconazole |
This product belongs to the azole antifungal drug with a wide antifungal spectrum. Its mechanism of action is to highly selectively interfere with the activity of fungal cytochrome P-450, thereby inhibiting the biosynthesis of ergosterol on the fungal cell membrane. It is effective against fungal infections in humans and various animals, including Candida infection, Cryptococcus neoformans infection, Malassezia furfur, Microsporum, Trichophyton, Epidermophyton, Blastomyces dermatitidis, Coccidioides immitis, Histoplasma capsulatum, F. fischeri, Cladosporium carinii, etc.
More
This product belongs to the azole antifungal drug with a wide antifungal spectrum. Its mechanism of action is to highly selectively interfere with the activity of fungal cytochrome P-450, thereby inhibiting the biosynthesis of ergosterol on the fungal cell membrane. It is effective against fungal infections in humans and various animals, including Candida infection, Cryptococcus neoformans infection, Malassezia furfur, Microsporum, Trichophyton, Epidermophyton, Blastomyces dermatitidis, Coccidioides immitis, Histoplasma capsulatum, F. fischeri, Cladosporium carinii, etc. |
86386-73-4 | 69 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Thiamine chloride |
It combines with pyrophosphate in the body to form a coenzyme, participates in the oxidative decarboxylation reaction of pyruvate and α-ketoglutarate in sugar metabolism, and is necessary for sugar metabolism. When it is deficient, oxidation is blocked to form pyruvate and lactic acid accumulation, which affects the body's energy supply and may lead to multiple peripheral neuritis (paresthesia, neuralgia, limb weakness, muscle aches and atrophy), as well as cardiovascular symptoms (palpitations, shortness of breath, chest tightness, cardiac hypertrophy, liver and lung congestion and peripheral edema) and digestive tract problems (loss of appetite, weakness, weight loss).
More
It combines with pyrophosphate in the body to form a coenzyme, participates in the oxidative decarboxylation reaction of pyruvate and α-ketoglutarate in sugar metabolism, and is necessary for sugar metabolism. When it is deficient, oxidation is blocked to form pyruvate and lactic acid accumulation, which affects the body's energy supply and may lead to multiple peripheral neuritis (paresthesia, neuralgia, limb weakness, muscle aches and atrophy), as well as cardiovascular symptoms (palpitations, shortness of breath, chest tightness, cardiac hypertrophy, liver and lung congestion and peripheral edema) and digestive tract problems (loss of appetite, weakness, weight loss). |
59-43-8 | 9 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Thiamine chloride |
It combines with pyrophosphate in the body to form a coenzyme, participates in the oxidative decarboxylation reaction of pyruvate and α-ketoglutarate in sugar metabolism, and is necessary for sugar metabolism. When it is deficient, oxidation is blocked to form pyruvate and lactic acid accumulation, which affects the body's energy supply and may lead to symptoms of the nervous and cardiovascular systems, such as multiple peripheral neuritis (paresthesia, neuralgia, limb weakness, muscle aches and atrophy, etc.), cardiovascular symptoms such as palpitations, shortness of breath, chest tightness, etc., and digestive symptoms such as decreased appetite leading to weakness and weight loss.
More
It combines with pyrophosphate in the body to form a coenzyme, participates in the oxidative decarboxylation reaction of pyruvate and α-ketoglutarate in sugar metabolism, and is necessary for sugar metabolism. When it is deficient, oxidation is blocked to form pyruvate and lactic acid accumulation, which affects the body's energy supply and may lead to symptoms of the nervous and cardiovascular systems, such as multiple peripheral neuritis (paresthesia, neuralgia, limb weakness, muscle aches and atrophy, etc.), cardiovascular symptoms such as palpitations, shortness of breath, chest tightness, etc., and digestive symptoms such as decreased appetite leading to weakness and weight loss. |
59-43-8 | 9 |